Seattle Genetics is on a mission. The goal: to deliver chemotherapy only to damaged cells in cancer patients while sparing healthy cells and avoiding all of the unpleasant side effects of traditional cancer treatments. This top biopharmaceutical company is already helping cancer patients by way of Antibody-Drug Conjugates (ADCs), including their own ADCETRIS® (brentuximab vedotin). Headed by President, CEO and Chairman of the Board Clay Seigall, PH.D., Seattle Genetics pushes forward with research and drug trials involving this favorable approach to cancer treatment.
Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript
ADCs target specific proteins found on cancerous cells in the body. They are then absorbed by those cells and release the chemotherapy contained within, destroying only those cells. By saving healthy cells in the body, ADCs make treatment and recovery more bearable for the patient. This alternative to surgery, radiation, hormone treatments and traditional chemotherapy is already improving quality of life for many people.
Seattle Genetics takes pride in their work and for Dr. Seigall, it is personal. He has experienced first-hand the loss of a loved one to brain cancer when his father passed away during his second year of grad school. His curiosity at his father’s appointments landed him at George Washington University where he earned his PH.D. in genetics. This was after earning a B.S. in Zoology at the University of Maryland, working with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. He serves on the Board of Directors of Alder BioPharmaceuticals and Mirna Therapeutics, two private biotechnology companies, and UltraGenyx, a biopharmaceutical company. He is an author on more than 70 publications and holds 15 patents.
While ADCs are targeting certain proteins located on the outside of cells, future studies will include innovative biopharmaceuticals that have the ability to target the inside of cells and the immune system. Seattle Genetics has grown considerably since their start in 1998. Despite rapid growth, the company maintains an atmosphere of integrity and scientific excellence and clearly displays an unwavering passion for helping patients.